INTRODUCTION
Ménière's disease, characterized by recurrent attacks of vertigo, fluctuating hearing loss (HL), and tinnitus, is a common disease with an incidence of 15-50 per 100,000 population. 1 Some patients with Ménière's disease are strongly prevented from participating in activities of daily life and interaction with their social environment, such as work and schooling, due to frequent attacks of vertigo, especially with progressive sensorineural HL, despite various kinds of medication. This type of Ménière's disease is called intractable Ménière's disease. Although the otopathology in Ménière's temporal bones was revealed in 1938 to be inner ear endolymphatic hydrops, 2,3 the definitive pathogenesis of Ménière's disease is still unknown and there is no radical treatment for the original pathogenesis of this disease.
It has, however, been reported that Ménière's disease is usually triggered by immune, metabolic, infectious, traumatic, or other insults to the inner ear 4 associated with a small misplaced malfunctioning endolymphatic sac. 5 Among these insults, immune-mediated responses in the inner ear endo-organs such as the endolymphatic sac, stria vascularis, and spiral ligament, are thought to be the main reason for the development of symptoms in Mé-nière's disease. 6 -9 Thus, systemic administration and/or local perfusion of corticosteroids into the middle ear have been adopted as an antiimmune or antiinflammatory therapy for patients with intractable Ménière's disease. 10, 11 These treatments were reported to result in good relief from vertigo and improvement of hearing in some cases. However, these results, especially for hearing, did not last long enough to discontinue additional repetitive applications of steroids. 12 Since Ménière's disease is characterized by repeated attacks of vertigo with fluctuating and/or progressive HL, unlike other inner ear diseases without recurrence such as sudden deafness and vestibular neuritis, it is necessary to refrain from repetitive applications of steroids for longterm follow-up with Ménière's patients because of side effects.
For inner ear drug delivery, we noted another hopeful but unevaluated route, the longitudinal route from the endolymphatic sac to the cochlea and vestibule, suggested by several lines of evidence in animal studies. Morgenstern et al. 13 and Lee et al. 14 demonstrated that the intraendolymphatic sac materials could reach the cochlear endolymphatic site through the vestibular aqueduct using a test marker and an ototoxic drug, respectively. Recently, Yamasoba et al. 15 suggested the possibility of gene therapy through the vestibular aqueduct route. We also revealed that intraendolymphatic sac steroids could upregulate a water channel molecule, aquaporin-3 mRNA, in the cochlea. 16 In this study, we examined the intraendolymphatic sac application of steroids as a new therapeutic strategy for intractable Ménière's disease.
MATERIALS AND METHODS

Patients
Patients were eligible for enrollment if they had received a clinical diagnosis of intractable Ménière's disease according to the 1995 American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) criteria. 17 These criteria can be briefly described as follows: 1) repeated attacks of vertigo-a definitive spell is spontaneous vertigo lasting at least 20 minutes and a mixed type of spontaneous nystagmus is observed during attacks; 2) fluctuating cochlear symptoms-the hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range (if necessary, we carried out a glycerol test or electrocochleogram to Fig. 1 . A flowchart of subjects in this randomized controlled study. Patients with Mé niè re's disease-like symptoms were sent by their home doctors to hospitals for appropriate treatments. Patients in the Kyoto district were sent to Kyoto Sosei Neurotologic Medical Center (Sosei Hospital; head ϭ Kitahara-M) and those in the Osaka district to Osaka Rosai Hospital (Rosai Hospital; head ϭ Okumura-S) / Osaka University Hospital (University Hospital; head ϭ Kubo-T). No mixture of patients in these two districts occurred in this study. Kitahara-M at Sosei Hospital evaluated patients with intractable Mé niè re's disease, enrolled and allocated drainage-accepted patients in Group-II (G-II: n ϭ 47) during 1996 to 2005. Kitahara-T at Rosai Hospital/University Hospital evaluated patients with intractable Mé niè re's disease, enrolled 150 cases into the study, and allocated drainage-accepted patients in Group-I (G-I: n ϭ 100) and drainage-declined patients in Group-III (G-III: n ϭ 50) during 1996 to 2005. detect endolymphatic hydrops); 18 and 3) exclusion of other causesto exclude other disorders, a thorough history, neurologic, neurotologic, and MRI examinations were carried out. Intractable Ménière's disease was designated in cases where various forms of medical and psychological managements failed for at least 6 months. Medical managements included diuretics, betahistine, diphenidol, dimenhydrinate, and diazepam, which were thought to be effective for persistent symptoms in Ménière's disease. 19 
Randomization and Treatment
Between April 1996 and March 2005, a total of 197 patients were enrolled and assigned to three study groups in a randomized controlled trial at three hospitals, Osaka Rosai Hospital (head: Okumura-S), Osaka University Hospital (head: Kubo-T), and Kyoto Sosei Neurotologic Medical Center (Kitahara-M). Group I (G-I) consisted of 100 patients who underwent endolymphatic sac drainage with steroid instillation into the sac and who were followed regularly for at least 2 years. Group II (G-II) consisted of 47 patients who underwent endolymphatic sac drainage without steroid instillation into the sac and who were followed regularly for at least 2 years. For steroid instillation into the endolymphatic sac in G-I, endolymphatic-sac drainage and steroid-instillation surgery 20 was performed. This surgery was designed in the same manner as the endolymphatic sac-expanding surgery 21 in G-II except for the instillation of steroids into the endolymphatic sac. Group III (G-III) consisted of 50 patients who declined endolymphatic sac drainage and thereafter continually received the best available non-surgical medical treatments mentioned above. 19 A randomized controlled study performed in this study is summarized as a flowchart in Figure 1 . The technical details of endolymphatic-sac drainage with steroid instillation are as follows: a simple mastoidectomy was performed, clearly exposing the endolymphatic sac in the area between the sigmoid sinus and the inferior margin of the posterior semicircular canal. If possible, the sac was exposed, including the rugose portion. The sac was opened with an L-(right ear) or backward L-(left ear) shaped incision made along the posterior and distal margins of the lateral wall. Then the sac was filled with a mass of 20 mg of prednisolone. While dissolving the mass in the sac, we prepared a bundle of absorbable gelatin films (ca. 4 ϫ 20 ϫ 0.7 mm ϫ 5 sheets) with fan-and stick-shaped ends. These films were tied to one another with biochemical adhesive (human thrombin combined with human fibrinogen) at the stickshaped end. The fan-shaped end was then inserted into the sac, and small pieces of absorbable gelatin sponge soaked in a high concentration of dexamethasone (32 mg/4 mL) were placed inside and outside the sac lumen expanded with the bundle. The sponges containing dexamethasone placed outside the sac were coated with the adhesive so that dexamethasone was slowly delivered into the sac over a long period of time as a natural sustained-release vehicle. The stick-shaped end extending out of the sac was fixed to the front edge of the mastoid cavity with the same adhesive so that the incision into the sac was also expanded as long as possible. The mastoid cavity was filled with relatively large pieces of absorbable gelatin sponge dipped in steroid antibiotic solution, after which the wound was closed with skin sutures. These two operations, steroid-instillation surgery in G-I patients and sac-expanding surgery in G-II patients, are schematically shown in Figure 2 .
Functional Examinations
A definitive spell lasting more than 20 minutes was regarded as a Ménière's vertigo attack according to the 1995 AAO-HNS criteria. 17 Frequency of vertigo was calculated based on the number of vertigo attacks during the 6 months before treatment. The number of attacks in G-III patients who refused endolymphatic sac drainage was also determined. Frequency of vertigo after treatment, for example, at the 3rd follow-up year was calculated based on the number of vertigo attacks during the 6 months between 30 and 36 months after treatment. Frequency of vertigo in G-III patients at this time point was also determined. "Complete" control of vertigo at the 3rd follow-up year meant no vertigo attacks during that period (0Ͻafter/ beforeՅ0.8 was regarded as better, 1.2Յafter/before as worse, and the others as no change).
Hearing function was measured by a pure tone audiometer and was evaluated based on the particularly weighted three-tone average formulated by (a ϩ 2b ϩ c)/4 (where a, b, and c are hearing levels at 0.5 kHz, 1 kHz, and 2 kHz, respectively) accord- ing to the modified 1995 AAO-HNS criteria. The worst hearing level during the 6 months before treatment was adopted as the hearing level before treatment and, for example, the worst hearing level during the 6 months between 42 and 48 months after treatment was adopted as the hearing level at the 4th follow-up year. More than 10 dB differences in hearing levels before and after treatment were regarded as better, less than Ϫ10 dB differences as worse, and the others as no change. Vestibular function was measured by a caloric test using an electronystagmogram (ENG). 22 For the caloric test, the external auditory canal was irrigated in turn with 30°C cold water and 44°C hot water (20 mL, respectively) for 10 seconds. The induced nystagmus was recorded using ENG in a dark, open-eyes situation. Based on the averaged maximum slow-phase eye velocity (max-SPEV) in the treated side, max-SPEV after treatment/max-SPEV before treatment was calculated and values of more than 1.1 were recognized as an improvement in vestibular function at the 2nd follow-up year.
Statistical Analysis
All the data from treatment results were presented as the ratio of the number of cases and treated statistically with the use of SPSS, version 14.0 (SPSS Inc, Chicago, IL). In each postoperative year result, the Mann-Whitney U test was used to analyze the data between each of two groups out of all three groups, G-I, G-II and G-III. All reported P values were two sided, and those under .05 were considered significant.
RESULTS
Patients' backgrounds in all three groups including sex, age, duration of disease, vertigo frequency before treatment, and stage of disease before treatment, are shown in Table I . Duration of disease indicates the period between the onset of symptoms and the date of treatment. Stage of disease is based on hearing. Stages I, II, III, and IV indicate that the particularly weighted three-tone average of the worst audiogram in the 6 months before treatment was Ͻ25, 25 to 40, 41 to 70 and Ͼ70, respectively. 17 As shown in Table I , there were no significant differences in patients' backgrounds among all three groups, G-I, G-II, and G-III.
According to the criteria in 1995 AAO-HNS, 17 longterm results in vertigo control and hearing improvement during the 2-to 7-year follow-up period in all groups are shown in Tables II and III (raw data) and Figure 3 (graphs) .
As shown in Figure 3A , vertigo attacks in G-I patients were completely suppressed (i.e., vertigo frequency ϭ 0) from 88.0 to 78.8% of patients during the 2-to 7-year follow-up period after treatment. Vertigo attacks in G-II patients were completely suppressed from 85.1 to 79.2% during the 2-to 7-year follow-up period. Vertigo attacks in G-III patients were completely suppressed from 8.0 to 25.0% during the 2-to 7-year-follow-up period.
As shown in Figure 3B , hearing in G-I patients improved (Ն10 dB) from 49.0 to 36.5% of patients and worsened (Յ-10 dB) from 7.0 to 13.5% during the 2-to 7-year follow-up period after treatment. Hearing in G-II patients improved from 31.9 to 8.3% and worsened from 12.8 to 37.5% during the 2-to 7-year follow-up period. Hearing in G-III patients improved from 6.0 to 0.0% and worsened from 42.0 to 75.0% during the 2-to 7-year follow-up period.
To compare the long-term results among all three groups, 2-year results demonstrated that definitive spells were completely controlled in 88.0% in G-I patients, 85.1% in G-II patients, and 8.0% in G-III patients (G-I ϭ G-IIϾG-III: Mann-Whitney). Hearing was improved in 49.0% in G-I patients, 31.9% in G-II patients, and 6.0% in G-III patients (G-IϾG-IIϾG-III: Mann-Whitney). Seven-year results showed that definitive spells were completely controlled in 78.8% in G-I patients, 79.2% in G-II patients, and 25.0% in G-III patients (G-I ϭ G-IIϾG-III: Mann-Whitney). Hearing was improved in 36.5% in G-I patients, 8.3% in G-II patients, and 0.0% in G-III patients (G-IϾG-II ϭ G-III: MannWhitney). Exact P values are all shown in Table II .
Vestibular function was examined in 56 out of 100 cases in G-I just before and 2 years after treatment. Two years after treatment, recovery of vestibular function occurred in just 50% (28 of the 56). In 28 of the 56 with improved vestibular function (Ն10%), vertigo was completely controlled in 26 (92.9%). In 28 of the 56 with nonimproved vestibular function (Ͻ10%), vertigo was completely controlled in 25 (89.3%). There were no significant differences in vertigo control between cases with improved or non-improved vestibular function after treatment. 
.62 E-10 Ͻ.001 P ϭ 5.47 E-10 Ͻ.001 P ϭ 6.91 E-9 Ͻ.001 n ϭ number; NS ϭ not significant; po2y ϭ 2 years postoperative; po3y ϭ 3 years postoperative; po4y ϭ 4 years postoperative; po5y ϭ 5 years postoperative; po6y ϭ 6 years postoperative; po7y ϭ 7 years postoperative.
DISCUSSION
Systemic administration and/or local perfusion of corticosteroids into the middle ear have sometimes been adopted as an antiimmune therapy for patients with intractable Ménière's disease. In a number of studies concerned with steroid treatment, only Shea et al. 10 and Sennarouglu et al. 11 observed steroid-treated patients for longer than 2 years in accordance with the 1995 AAO-HNS criteria. 17 Sennarouglu et al. reported that intratympanic perfusion of dexamethasone suppressed vertigo completely in 42.0% of patients and improved hearing significantly in 16.0% 2 years after treatment. Shea et al. demonstrated that systemic and intratympanic combined administration of dexamethasone suppressed vertigo completely in 63.4% and improved hearing significantly in 35.4% 2 years after treatment. On the other hand, Silverstein et al. 12 suggested that intratympanic application of dexamethasone showed no significant benefit over placebo in their prospective, randomized, double-blind, crossover trial. In fact, these studies showed that steroid treatment appeared to result in good relief of vertigo and improvement of hearing in some cases. However, there were limitations in the long-term findings of systemic and/or intratympanic steroid application, and it often happened to consider additional repetitive applications of steroids for recurrences of symptoms, especially progressive HL, along with the risk of side effects.
Endolymphatic sac surgery, which was first performed by Portmann 23 in 1927 is another option for patients with intractable Ménière's disease. Thomsen et al., 24 Pillsbury et al. 25 and Bretlau et al. 26 suggested that endolymphatic sac surgery was no more effective than a placebo. Despite this controversy, endolymphatic sac surgery is still a commonly performed procedure worldwide. 27 This kind of conservative surgery is thought to be effective for inner ear decompression against endolymphatic hydrops and several modifications of this surgery have been tried and reported. Moffat et al., 28 Huang et al., 29 Gibson et al. 30 and Gianoli et al. 31 reported 2-year results of their modified endolymphatic sac surgery as follows: complete control of vertigo in 43.0%, 84.4%, 56.8%, and 60.0% of patients, respectively, and significant hearing improvement in 19.0%, 12.8%, 4.7%, and 60.0% of patients, respectively. Ostrowski et al., 32 however, followed up Gianoli's results for 4 to 5 years, which resulted in 47.0% having complete control of vertigo and 18.0% having significant hearing improvement. Goin et al. 33 suggested that endolymphatic sac surgery did not modify the natural course of Ménière's disease with respect to hearing. Stahle et al. 34 suggested that Ménière's patients were more annoyed with progressive HL rather than vertigo attacks during long-term follow-up because of spontaneous relief of vertigo over the years. With the poor long-term results in hearing with systemic and/or intratympanic application of steroids and endolymphatic surgery mentioned above, it is time to think of ways to improve and maintain the inner ear function, especially hearing, in patients with intractable Ménière's disease.
In our study, it was demonstrated that long-term results of treatment in G-I patients were excellent, as seen in Figure 3 . The intraendolymphatic sac application of large doses of steroids in G-I patients could have additional effects to those of endolymphatic sac-expanding surgery in G-II patients, especially on hearing, and was, of course, superior to non-surgical treatment of intractable Ménière's disease in G-III patients, both for vertigo control and hearing improvement for at least 7 years.
Our study has limitations. From the long and controversial history of evaluations of surgical treatments for intractable Ménière's disease, [25] [26] [27] it is well understood that it is necessary to include a non-surgical control group when surgical effects are evaluated because of the spontaneous relief of symptoms. However, as mentioned above, endolymphatic sac drainage is a very common strategy for patients with intractable Mé-nière's disease. 28 It would thus be difficult to not apply drainage to some patients for a perfect randomized controlled trial. Therefore, in the G-III group, we included only 50 patients who declined to undergo endolymphatic sac drainage. As well, it was confirmed that there were no significant differences in patients' backgrounds among all three groups, G-I, G-II, and G-III.
A high concentration of intraendolymphatic sac steroids in G-I patients could have almost the same effects on vertigo control and make additional effects on hearing 
CONCLUSIONS
From non-surgical observation in G-III patients for at least 7 years after treatment, steroids instilled into endolymphatic sac in G-I patients significantly improved hearing in intractable Ménière's patients, more so than endolymphatic sac drainage without steroids in G-II patients.
